Patents Assigned to The U.S.A, as represented by the Secretary, Department of Health and Human Services
-
Patent number: 11970528Abstract: Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.Type: GrantFiled: February 3, 2020Date of Patent: April 30, 2024Assignees: LENTIGEN TECHNOLOGY, INC., The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
-
Publication number: 20240117026Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.Type: ApplicationFiled: August 2, 2023Publication date: April 11, 2024Applicants: The U.S.A., as Represented by the Secretary, Department of Health and Human Services, Sanaria Inc.Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
-
Publication number: 20240117011Abstract: Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies.Type: ApplicationFiled: February 4, 2022Publication date: April 11, 2024Applicant: The U.S.A., as Represented by the Secretary, Department of Health and Human ServicesInventors: John Misasi, Lingshu Wang, Chaim Aryeh Schramm, John R. Mascola, Daniel Cesar Douek, Nancy J. Sullivan, Amy Ransier Henry, Tongqing Zhou, Peter D. Kwong, Wei Shi, Yi Zhang, Eun Sung Yang, Mario Roederer, Rosemarie Diana Mason, Amarendra Pegu, Julie E. Ledgerwood
-
Publication number: 20240041906Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.Type: ApplicationFiled: August 17, 2023Publication date: February 8, 2024Applicant: The U.S.A., as Represented by the Secretary, Department of Health and Human ServicesInventors: Walid Heneine, Thomas M. Folks, Robert Janssen, Ronald A. Otten, Jose Gerardo Garcia Lerma
-
Publication number: 20240041978Abstract: Methods are disclosed herein for modulating osteoclast fusion. In some embodiments, these methods include administering an effective amount of a Lupus autoantigen (La) protein, or an agent that modulates La protein expression or activity, to a subject in need thereof, thereby modulating osteoclast fusion in the subject. In some embodiments, the method increases osteoclast fusion and bone resorption. In other embodiments, the method decreases osteoclast fusion and bone resorption.Type: ApplicationFiled: March 3, 2022Publication date: February 8, 2024Applicant: The U.S.A., as Represented by the Secretary, Department of Health and Human ServicesInventors: Leonid V. Chernomordik, Evgenia Leikina, Jarred M. Whitlock
-
Patent number: 11878052Abstract: Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.Type: GrantFiled: January 27, 2020Date of Patent: January 23, 2024Assignees: Lentigen Technology, Inc., The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
-
Publication number: 20230405027Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.Type: ApplicationFiled: May 19, 2023Publication date: December 21, 2023Applicant: THE U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Walid Heneine, Thomas M. Folks, Robert Janssen, Ronald A. Otten, Jose Gerardo Garcia Lerma
-
Publication number: 20230406953Abstract: Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin-specific monoclonal antibody, fused to a CD8? hinge region, a CD8? transmembrane region, a 4-1BB co-stimulatory domain and a CD3? signaling domain. Isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.Type: ApplicationFiled: July 26, 2023Publication date: December 21, 2023Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Nan Li, Dan Li
-
Publication number: 20230390313Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.Type: ApplicationFiled: June 6, 2023Publication date: December 7, 2023Applicant: THE U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Walid Heneine, Thomas M. Folks, Robert Janssen, Ronald A. Otten, Jose Gerardo Garcia Lerma
-
Publication number: 20230390322Abstract: Methods are disclosed for treating a subject with a cobalamin C (cblC) deficiency. These methods include selecting a human subject with the cblC deficiency; and administering about 5 mg to about 10 grams of methylcobalamin (MeCbl) daily to the human subject. Methods also are disclosed for treating a fetus with a cobalamin C (cblC) deficiency. The methods include selecting a female human subject pregnant with the fetus that has the cblC deficiency; and administering about 5 mg to about 10 grams of MeCbl daily to the female human subject, in order to treat the cblC deficiency in the fetus. Optionally, OHCbl can be administered to the subject.Type: ApplicationFiled: October 12, 2021Publication date: December 7, 2023Applicant: THE U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Charles P. Venditti, Jennifer Lyn Sloan, Eirini Manoli
-
Publication number: 20230391852Abstract: Polypeptides that specifically bind the spike (S) protein of human coronavirus, selected from six camel VHH single domain antibody phage display libraries, are described. The S protein-specific polypeptides disrupt binding of the SARS-CoV-2 and/or SARS-CoV S protein to the cellular receptor ACE2, which is important for neutralization of the virus. Use of the S protein-specific polypeptides for the diagnosis and treatment of SARS-CoV-2 and/or SARS-CoV is described.Type: ApplicationFiled: October 26, 2021Publication date: December 7, 2023Applicant: The U.S.A., as Represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Jessica Diana Hong
-
Patent number: 11827889Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.Type: GrantFiled: October 6, 2022Date of Patent: November 28, 2023Assignee: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventor: James N. Kochenderfer
-
Publication number: 20230348568Abstract: Monoclonal antibodies that specifically bind gp42 of Epstein-Barr virus (EBV) are described. The antibodies are capable of blocking fusion of EBV-infected cells and neutralizing EBV infection. Use of the EBV-specific monoclonal antibodies, and conjugates thereof, for the treatment and prophylaxis of EBV infection is also described.Type: ApplicationFiled: February 19, 2021Publication date: November 2, 2023Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey I. Cohen, Wei Bu, Nathan Board, Kennichi Dowdell
-
Patent number: 11802163Abstract: Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin-specific monoclonal antibody, fused to a CD8? hinge region, a CD8? transmembrane region, a 4-1BB co-stimulatory domain and a CD3? signaling domain. Isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.Type: GrantFiled: November 7, 2018Date of Patent: October 31, 2023Assignee: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Nan Li, Dan Li
-
Publication number: 20230338507Abstract: Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.Type: ApplicationFiled: February 6, 2023Publication date: October 26, 2023Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Rui Kong, Tongqing Zhou, John Mascola, Kai Xu, Cheng Cheng, Gwo-Yu Chuang, Kevin Liu, Baoshan Zhang, Li Ou, Wing-Pui Kong
-
Publication number: 20230340146Abstract: Optimized chimeric antigen receptors (CARs) targeting glypican-1 (GPC1) that include a 12-amino acid hinge region from IgG4 are described. The optimized CARs include a transmembrane domain from either CD8 or CD28. Immune cells, such as T cells or natural killer cells, expressing the optimized CARs can be used to treat GPC1-positive solid tumors.Type: ApplicationFiled: August 10, 2021Publication date: October 26, 2023Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Nan Li, Jessica Diana Hong
-
Publication number: 20230331832Abstract: Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.Type: ApplicationFiled: May 15, 2023Publication date: October 19, 2023Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey Baron, Crystal Sao Fong Cheung, Julian Chun Kin Lui, Dimiter Dimitrov, Zhongyu Zhu
-
Publication number: 20230312706Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.Type: ApplicationFiled: May 16, 2023Publication date: October 5, 2023Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, The U.S.A. as Represented by the Secretary, Department of Health and Human ServicesInventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng
-
Patent number: 11773396Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.Type: GrantFiled: October 6, 2022Date of Patent: October 3, 2023Assignee: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventor: James N. Kochenderfer
-
Publication number: 20230266306Abstract: Identification of immunodominant Babesia microti antigens using genome-wide immunoscreening is described. Candidate antigens were screened against sera from patients with clinical babesiosis. Also described are diagnostic assays with high sensitivity and specificity for detecting B. microti-specific antibodies in patient samples using the identified immunodominant antigens.Type: ApplicationFiled: March 21, 2023Publication date: August 24, 2023Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Sanjai Kumar, Nitin Verma, Ankit Puri